Gene
IGF2
IGF2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (50), Actionable biomarkers (1), Trial mentions (12), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention IGF2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 dated before 1990 and 4 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 17 of 11,460 | 0.15% |
| 2022 | 0 of 8,285 | 0.00% | 24 of 13,598 | 0.18% |
| 2021 | 1 of 8,692 | 0.01% | 35 of 15,045 | 0.23% |
| 2020 | 1 of 7,640 | 0.01% | 30 of 14,459 | 0.21% |
| 2019 | 0 of 7,300 | 0.00% | 28 of 12,159 | 0.23% |
| 2018 | 0 of 6,927 | 0.00% | 23 of 11,854 | 0.19% |
| 2017 | 0 of 6,558 | 0.00% | 28 of 11,595 | 0.24% |
Showing 10 of 37 years.
Assay-provider ledger (50)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Canhelp Genomics | Diagnostic provider | Clinical validation | 1 | December 01, 2024 |
| Cepheid | Diagnostic provider | Clinical validation | 1 | March 01, 2018 |
| KAPA Biosystems | Reagent supplier | Clinical validation | 1 | February 27, 2018 |
| NanoDrop Technologies | Reagent supplier | Clinical validation | 1 | February 27, 2018 |
| ROCHE | Context dependent | Clinical validation | 1 | February 27, 2018 |
Showing 5 of 50 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| IGF2 amplification | Egfr Mab Inhibitors | responsive | colorectal adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (12)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03576963 | Trial eligibility (AACT) |
| NCT07497477 | Trial eligibility (AACT) |
| NCT02028221 | Trial outcomes (AACT) |
| NCT01721577 | Trial outcomes (AACT) |
| NCT01041027 | Trial outcomes (AACT) |
Showing 5 of 12 trial mentions.
Target-disease associations (387)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abdominal obesity | nutritional or metabolic disease | Literature (Europe PMC) |
| Abnormal sperm morphology | phenotype | Literature (Europe PMC) |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Anxiety | phenotype | Literature (Europe PMC) |
Showing 5 of 387 associations.
Vendor sourcing (38)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v4.1.0 dataset. Predicted Consequence/Location: Missense variant In silico tool predictions suggest damaging effect... | View ClinVar record SCV007610919.1 |
| Albert Einstein College of Medicine | Trial sponsor | Mentioned in trial textTrial free-text mention | IGF2 | View trial NCT01041027 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.100G>C (p.G34R) alteration is located in exon 2 (coding exon 1) of the IGF2 gene. This alteration results from a G to C substitution at nucleotide posi... | View ClinVar record SCV003549985.2 |
| Assistance Publique – Hôpitaux de Paris | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. "Negative control" population: subjects who have undergone genetic exploration and: * Having had a study of normal methylation of the 11p15 region ... | View trial NCT07497477 |
| Assistance Publique – Hôpitaux de Paris | Trial sponsor | Mentioned in trial textTrial free-text mention | IGF2 | View trial NCT07497477 |
Showing 5 of 38 sourcing records.
Trial-cited literature (470)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Reciprocal regulation of hMENA and TGF-β signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC. | Journal for immunotherapy of cancer | 2026 | 1 |
| Cardiometabolic function in Offspring, Mother and Placenta after Assisted Reproductive Technology (COMPART): a prospective cohort study. | BMJ open | 2025 | 0 |
| Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy. | Neuro-oncology | 2024 | 23 |
| Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial. | British journal of cancer | 2024 | 23 |
| c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment. | Cell communication and signaling : CCS | 2023 | 148 |
Showing 5 of 470 papers.
Literature-extracted relations (79)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Anhydrous glucose | Chemical | positive_correlate |
Preptin: A New Bone Metabolic Parameter? | 2023 |
| Anhydrous glucose | Chemical | positive_correlate |
Maternal serum preptin levels in the pathogenesis and diagnosis of Gestational diabetes mellitus. | 2023 |
| (R,S)-ketamine (Pilot I) | Chemical | positive_correlate |
The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity. | 2022 |
| Anhydrous glucose | Chemical | positive_correlate |
Cytokines and Hormones That Contribute to the Positive Association between Fat and Bone. | 2014 |
| Anhydrous glucose | Chemical | associate |
Three new players in energy regulation: preptin, adropin and irisin. | 2014 |
Showing 5 of 79 relation assertions.
Organizations publishing (384)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 24 | 2000 to 2024 |
| Harvard Medical School | Academic | 13 | 2011 to 2022 |
| Mass General Brigham | Hospital | 12 | 2011 to 2023 |
| The University of Texas System | Academic | 10 | 2009 to 2024 |
| Dana-Farber Cancer Institute | Other | 9 | 2005 to 2022 |
Showing 5 of 384 organizations.
Where IGF2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
361 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, protein variant mentions, and human sample screening reference.